MAPT and Alzheimer disease: The current emphasis on AD diagnostics is centered around the progressively changing core of biomarkers linked to the ATN (Amyloid, Tau, neurodegeneration) framework, which acknowledges AD’s complexity and utilizes resources to generate relevant data via the analysis of body fluids, neuroimaging, and the integration of common co-pathologies [4,5].